Medigen Biotechnology Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,065	1,324	1,388	2,223	2,041	2,145
Short-Term Investments	1,780	1,161	1,185	2,364	3,040	800
Trading Asset Securities	0.3	0.31	0.59	0.49	54.23	53.6
Cash & Short-Term Investments	2,846	2,485	2,574	4,588	5,135	2,998
Cash Growth	10.04%	-3.44%	-43.90%	-10.67%	71.28%	32.62%
Accounts Receivable	236.58	277.39	286.07	328.89	398.31	800.22
Other Receivables	24.55	69.79	87.61	124.72	66.37	35.46
Receivables	261.13	347.18	373.67	453.61	464.69	835.68
Inventory	651.81	581.27	645.06	546.91	692.62	752.87
Prepaid Expenses	-	27.58	22.76	33.61	382.35	99.59
Other Current Assets	119.59	45.71	46.09	86.4	57.93	231.96
Total Current Assets	3,878	3,487	3,661	5,708	6,733	4,918
Property, Plant & Equipment	2,034	1,867	1,981	2,043	2,198	2,189
Long-Term Investments	479.29	480.78	640.35	292.87	307.33	363.71
Goodwill	-	76.18	76.18	76.18	76.18	76.18
Other Intangible Assets	92.39	18.06	24.18	30.36	36.9	48.08
Long-Term Deferred Tax Assets	203.07	204.58	253.21	327.5	480.94	522.18
Other Long-Term Assets	260.61	47.18	74.12	49.1	150.42	81.75
Total Assets	6,947	6,181	6,710	8,527	9,982	8,199
Accounts Payable	112.93	98.59	125.29	122.57	185.01	163.94
Short-Term Debt	155.6	169.6	229.8	402.6	328	300
Current Portion of Long-Term Debt	38.46	28.6	47.35	1,728	28.86	21.34
Current Portion of Leases	24.93	17.93	22	17.32	13.13	3.32
Current Income Taxes Payable	15.83	12.66	12.73	24.63	22.99	-
Current Unearned Revenue	155.95	161	231.23	135	130.4	244.42
Other Current Liabilities	212.68	256.29	256.82	349.37	343.94	331.89
Total Current Liabilities	716.37	744.65	925.22	2,780	1,052	1,065
Long-Term Debt	1,117	421.32	411.25	449.1	2,129	470.77
Long-Term Leases	370.94	273.81	308	267.53	275.32	196.64
Pension & Post-Retirement Benefits	1.28	0.6	3.61	9.16	10.69	10.83
Long-Term Deferred Tax Liabilities	14.06	14.06	14.08	14.15	14.24	14.35
Other Long-Term Liabilities	10.12	10.12	10.28	10.28	29.53	15.89
Total Liabilities	2,230	1,465	1,672	3,530	3,511	1,773
Common Stock	1,393	1,393	1,393	1,393	1,394	1,394
Additional Paid-In Capital	669.84	668.55	536.79	968.14	1,562	1,109
Retained Earnings	-514.61	-461.46	-352.66	-747.51	-727.98	-52.82
Comprehensive Income & Other	-53.79	-50.66	4.69	-22.45	-34.12	-54.96
Total Common Equity	1,495	1,549	1,582	1,592	2,194	2,394
Minority Interest	3,223	3,167	3,456	3,405	4,277	4,032
Shareholders' Equity	4,718	4,716	5,038	4,997	6,471	6,426
Total Liabilities & Equity	6,947	6,181	6,710	8,527	9,982	8,199
Total Debt	1,707	911.25	1,018	2,865	2,774	992.07
Net Cash (Debt)	1,139	1,574	1,555	1,723	2,361	2,006
Net Cash Growth	-28.87%	1.21%	-9.72%	-27.03%	17.68%	85.87%
Net Cash Per Share	8.15	11.30	11.16	12.36	16.97	14.44
Filing Date Shares Outstanding	139.87	139.31	139.31	139.35	139.45	139.36
Total Common Shares Outstanding	139.87	139.31	139.31	139.35	139.45	139.36
Working Capital	3,162	2,742	2,736	2,928	5,681	3,853
Book Value Per Share	10.69	11.12	11.36	11.42	15.73	17.18
Tangible Book Value	1,402	1,455	1,482	1,485	2,081	2,270
Tangible Book Value Per Share	10.02	10.45	10.64	10.66	14.92	16.29
Land	-	330.29	330.29	330.29	354.04	354.04
Buildings	-	1,477	1,468	1,465	1,506	1,500
Machinery	-	1,265	1,233	1,266	1,240	1,178
Construction In Progress	-	-	2.57	21.37	14.54	4.7
Leasehold Improvements	-	9.54	9.35	3.34	3.03	2.55